Avid Bioservices Appoints Timothy Compton as Chief Commercial OfficerHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Avid Bioservices Appoints Timothy Compton as Chief Commercial OfficerGlobeNewswireJanuary 8, 2020ReblogShareTweetShareCompany Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management ExperienceTUSTIN, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Timothy Compton as chief commercial officer.  Mr. Compton is an accomplished professional who possesses extensive experience in commercial operations, including sales team management, business development, marketing and corporate development.  In his new role, he will be responsible for driving the continued growth of Avid’s CDMO business, including the ongoing expansion of the company’s commercial and clinical client base.  Mr. Compton is replacing Tracy Kinjerski, who has left the company to pursue other opportunities.Mr. Compton most recently served as senior director of sales and business development for Cambrex Corporation, a leading small molecule CDMO, where he managed the company’s Western North America and Asia Pacific CDMO sales and business development team.  Following Cambrex’s 2019 acquisition of Avista Pharma Solutions, he played a key role in transitioning Avista’s commercial operations practices to Cambrex.  Prior to its sale to Cambrex, Mr. Compton was vice president of sales for Avista, overseeing sales, business development and business operations across all the company’s service offerings, driving significant year-over-year revenue growth.  Mr. Compton held multiple senior level positions with AAIPharma Services Corporation, a CDMO now named Alcami, including executive director of alliance management and  executive director of business development.  His career has also included tenures with a range of life science companies including Baypoint Biosystems, N.V. Organon, Kadmus Pharmaceuticals and Atairgin Technologies.  “We are excited to have Tim join the Avid team and contribute his broad CDMO industry experience to the continued growth and expansion of our business.  His track record of driving impressive sales and revenue growth in this space positions him ideally to serve as Avid’s chief commercial officer,” said Rick Hancock, interim president and chief executive officer of Avid.  “On behalf of the company, I’d also like to express my gratitude to Tracy Kinjerski for the important contributions that she made during her time with Avid.  We wish her well in all of her future endeavors.”About Avid Bioservices, Inc.Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.comContacts:Stephanie Diaz (Investors) Vida Strategic Partners415-675-7401sdiaz@vidasp.com Tim Brons (Media)           Vida Strategic Partners  415-675-7402                                                                     tbrons@vidasp.comStory continuesReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextSBA Veterans Small Business Advisory Committees to Host Public Meetings March 4 and 5PR NewswireIndonesian entertainment development company Visinema raises $3.25 million Series ATechCrunchBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinancePersonal loans growth rate rises, impacts retailersYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance